Fundamental Data for PPHM

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.

# Employees: 138

Address: 14272 Franklin Avenue Suite 100,Tustin,CA,USA

Phone: 714 508-6000

Fax: 714 838-5817

Website: www.peregrineinc.com

Email: ir@peregrineinc.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Steven W. King (Presi.; C.E.O.)

Paul J. Lytle (C.F.O.)

David H. Pohl (Dir.)

Carlton M. Johnson (Dir.)

Eric S. Swartz (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 7/31/2009

Next Earnings Date(Expected): 12/9/2009

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	PPHM	Compare to S&P
YTD	103.45 %	68.38 %
4 Weeks	-8.39 %	-9.37 %
12 Weeks	-21.31 %	-25.82 %

Shares Information

Analyst Coverage: N

Avg Volume: 170241

Shares Outstanding: 47M

Market Cap: $0.14B

52 Week High: $4.85

52 Week Low: $1.10

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 10/19/2009 PPHM split by factor of 0.200

Earnings Performance

EPS Growth in Last Quarter: 50.00 %

EPS Growth in Last Year: 50.00 %

Sales Growth in Last Quarter: -14.20 %

Sales Growth in Last Quarter: 344.96 %

Financials

Qtr Book Value: $26.78

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010